Chemotherapy for lung cancer in Uni-asia Cancer hospital

Chemotherapy for lung cancer at Uni-asia Cancer Hospital in Chengdu, China, provides patients with advanced systemic and targeted treatment options. The hospital focuses on minimally invasive oncology and uses specific methods like transarterial chemoembolization (TACE) to deliver drugs directly to the tumor. This facility has treated 3,000+ lung cancer patients, reporting a 95% clinical effectiveness rate for those who complete their full treatment course.

Expert Medical Team

The oncology department is led by Prof. Dr. Liao Zhengyin, a Chief Physician with experience performing 40,000+ procedures. Prof. Dr. Liao Zhengyin served as a Senior Visiting Scholar at Johns Hopkins Hospital in the USA and leads a multidisciplinary team for complex cases. Dr. Luo Jiamin, the Deputy Director of Oncology Ward II, works alongside him. Dr. Luo Jiamin holds a Master’s degree in Oncology and specializes in combining immunotherapy with local treatments for advanced tumors. The hospital brings together specialists from top medical institutions in China to create individualized care plans.

Advanced Delivery Methods

The hospital offers different ways to receive chemotherapy based on the patient's specific needs. Standard systemic chemotherapy is delivered intravenously to reach cancer cells throughout the body. For more localized treatment, doctors use transarterial chemoembolization (TACE). This method delivers chemotherapy directly into the arteries that feed the tumor. It helps reduce side effects in the rest of the body while protecting healthy tissue. This approach is often combined with immunotherapy or radiotherapy for better results.

Precision Testing and Individualized Care

Treatment begins with detailed biomarker testing to identify specific mutations. Doctors test for EGFR, ALK, ROS1, BRAF, MET, RET, and KRAS mutations, along with PD-L1 expression. This data helps the multidisciplinary team choose the most effective drugs for each person. A team of experts in surgery, pathology, imaging, and internal medicine reviews every case together. This teamwork helps patients achieve an average survival extension of over 10 months. You can leave a request on Bookimed to receive a consultation about these treatment options.